Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.79 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.58 |
| ▸ | GSK3A | P49840 | 3/20 | 0.58 |
| ▸ | GSK3B | P49841 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | INSR | P06213 | 2/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672282 | 0.88 | KDR (1.00) | KDRBRAFFGFR2GSK3AGSK3B | |
| SCHEMBL4996941 | 0.88 | KDR (0.81) | KDRBRAFFGFR2GSK3AGSK3B | |
| SCHEMBL1123240 | 0.87 | KDR (0.67) | KDRBRAFFGFR2GSK3AGSK3B | |
| SCHEMBL1122025 | 0.86 | KDR (0.70) | KDRBRAFFGFR2GSK3AGSK3B | |
| SCHEMBL4996034 | 0.86 | KDR (0.74) | KDRBRAFFGFR2GSK3AGSK3B | |
| SCHEMBL4996001 | 0.84 | BRAF (0.64) | KDRBRAFFGFR2GSK3AGSK3B | |
| SCHEMBL4992140 | 0.81 | KDR (0.54) | KDREGFR | |
| SCHEMBL5000792 | 0.81 | BRAF (0.55) | KDRBRAF | |
| SCHEMBL14017635 | 0.81 | KDR (0.73) | KDRBRAFFGFR2GSK3AGSK3B | |
| SCHEMBL1121971 | 0.77 | CDK2 (0.70) | KDRBRAFFGFR2GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
| EP-1694670-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC Biotech AG (DE) | 2006-08-30 | — | — | EP | claimed |
| WO-2005058876-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC BIOTECH AG (DE) | 2005-06-30 | — | — | WO | claimed |
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | KDR 2202/4885BRAF 478/4885FGFR2 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.